Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials

W. Tillett1,2, C.-Y. Lin3, A. Trevelin Sprabery3, J.A. Birt4, A. Kavanaugh4

1Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK;
2Department of Pharmacy and Pharmacology, University of Bath, UK;
3Eli Lilly and Company, Indianapolis, USA;
4University of California, San Diego (UCSD) School of Medicine, Division of Rheumatology, Allergy, and Immunology, San Diego, USA.

Please address correspondence to: William Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, United Kingdom. E-mail: w.tillett@nhs.net

Received on November 8, 2019; accepted in revised form on April 20, 2020.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2020.

Key words: biologic-naive, TNFi-experienced, ixekizumab, work productivity, psoriatic arthritis

Trial registration:
SPIRIT-P1: NCT01695239;
SPIRIT-P2: NCT02349295.

Funding: this study was funded by Eli Lilly and Company, Indianapolis, IN, USA.

Competing interests: W. Tillett has received grants/speaker fees and/or honoraria from AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; C.-Y. Lin is a full-time employee of Eli Lilly and minor stock holder; A. Trevelin Sprabery and J.A. Birt are employees and shareholder of Eli Lilly and Company; A. Kavanaugh reports consulting for Eli Lilly and Company.

ABSTRACT

Objective. To determine the proportion of patients in Phase 3 studies (SPIRIT-P1 and SPIRIT-P2) who achieved minimal clinically important difference (MCID) for work productivity loss and activity impairment domains of Work Productivity and Activity Impairment Specific Health Problem (WPAI-SHP) questionnaire.

Methods. In the SPIRIT-P1 study, comprising a 24-week double-blind treatment period, biologic-naive patients with active psoriatic arthritis (PsA) were randomised to ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W) (starting dose of 160 mg), adalimumab 40 mg every 2 weeks (ADAQ2W), or placebo. SPIRIT-P2 enrolled tumour necrosis factor inhibitor (TNFi)-experienced patients who were randomised to receive IXEQ4W, IXEQ2W or placebo for 24 weeks of double-blind treatment. In this post-hoc analysis, we investigated the proportion of patients in SPIRIT-P1 and P2 studies who achieved 15% improvement in work productivity loss and 20% improvement in activity impairment domains of WPAI-SHP during double-blind treatment period.

Results. In SPIRIT-P1, at Week 24, 57.1% and 55.8% of biologic-naive patients on IXEQ4W and ADAQ2W respectively, achieved MCID estimates for work productivity loss compared to 25.6% of patients treated with placebo. The proportion of ixekizumab- and adalimumab-treated patients achieving MCIDs for activity impairment were significantly higher (IXEQ4W: p<0.001; ADAQ2W: p=0.001) compared to placebo-treated patients at Week 24. In SPIRIT-P2, significantly more TNFi-experienced patients on IXEQ4W (p<0.001) achieved MCIDs compared to placebo at Week 24.

Conclusion. Treatment with ixekizumab was associated with clinically meaningful improvements in WPAI-SHP domains in biologic-naive and TNFi-experienced patients with active PsA.

Introduction

Psoriatic arthritis (PsA) is an inflammatory articular disease of joint, spine or entheses in patients with current or history of psoriasis (1). Psoriatic arthritis can result in irreversible joint damage leading to substantial negative impact on physical function, quality of life and ability to work (2). The population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey reported significant negative impact of PsA on work productivity and employment status (3). In this survey, nearly one-third of patients reported difficulty in working full time or missed work within the past 12 months (3). It is associated with high levels of unemployment up to 50% and work disability up to 39% and patients begin to experience work disability very early in the course of the disease prior to diagnosis (4, 5).

The Work Productivity and Activity Impairment Specific Health Problem (WPAI-SHP) questionnaire assesses the impact of disease on work productivity and activities outside of work (6). Ixekizumab is a high-affinity monoclonal antibody that selectively targets IL-17A. In two Phase 3 studies of ixekizumab, significant improvements were reported in three of four WPAI-SHP domains in patients treated with ixekizumab and adalimumab (SPIRIT-P1) and patients treated with ixekizumab (SPIRIT-P2) as compared to placebo. These improvements were maintained in ixekizumab-treated patients until Week 52 (7, 8).

Minimal clinically important difference (MCID) is the minimal difference that patients perceive as beneficial and is a standard approach to assess clinical importance across studies for changes in patient-reported outcomes (PROs) (9). Studies reporting improvements in WPAI-SHP did not assess clinical meaningfulness of these improvements, as MCID estimates were not yet available for patients with active PsA (7, 8). Tillett and colleagues estimated the MCIDs for work productivity loss and activity impairment domains as 15% and 20% improvement from baseline, respectively, among biologic-naive and tumour necrosis factor inhibitor (TNFi)-experienced patients with PsA (10). This study assessed the proportion of patients in SPIRIT-P1 and SPIRIT-P2 studies achieving MCID for improvements in work productivity.
Table I. Baseline employment status and WPAI-SHP domain scores in SPIRIT-P1 and SPIRIT-P2 studies (7, 8, 10).

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>SPIRIT-P1 (Biologic-naive)</th>
<th>SPIRIT-P2 (TNFi-experienced)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PBO (n=106)</td>
<td>ADAQ2W (n=101)</td>
</tr>
<tr>
<td>Work for pay (full time)</td>
<td>48 (45.3)</td>
<td>47 (46.5)</td>
</tr>
<tr>
<td>Work for pay (part time)</td>
<td>13 (12.3)</td>
<td>15 (14.9)</td>
</tr>
<tr>
<td>Unable to work due to PsA</td>
<td>9 (8.5)</td>
<td>11 (10.9)</td>
</tr>
<tr>
<td>Unable to work due to non-PsA reasons</td>
<td>6 (5.7)</td>
<td>6 (5.9)</td>
</tr>
<tr>
<td>Volunteer</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Unable to work due to non-PsA reasons</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Other</td>
<td>30 (28.3)</td>
<td>22 (21.8)</td>
</tr>
<tr>
<td>Unable to work due to PsA</td>
<td>6 (5.7)</td>
<td>6 (5.9)</td>
</tr>
<tr>
<td>Unable to work due to non-PsA reasons</td>
<td>2 (1.9)</td>
<td>1 (1.0)</td>
</tr>
<tr>
<td>Volunteer</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Housekeeping</td>
<td>6 (5.7)</td>
<td>4 (4.0)</td>
</tr>
<tr>
<td>Retired</td>
<td>21 (19.8)</td>
<td>17 (16.8)</td>
</tr>
<tr>
<td>Student</td>
<td>2 (1.9)</td>
<td>1 (1.0)</td>
</tr>
<tr>
<td>Missing</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

WPAI-SHP domains, mean (SD)

- % Activity impairment: 46.1 (24.7) vs 46.9 (26.0)
- % Presenteeism: 32.4 (21.2) vs 40.6 (25.2)
- % Absenteeism: 8.9 (24.5) vs 9.2 (21.0)
- % Work productivity: 34.6 (23.4) vs 42.3 (28.5)

WPAI-SHP domains, mean (SD)

- % Activity impairment: 46.1 (24.7) vs 46.9 (26.0)
- % Presenteeism: 32.4 (21.2) vs 40.6 (25.2)
- % Absenteeism: 8.9 (24.5) vs 9.2 (21.0)
- % Work productivity: 34.6 (23.4) vs 42.3 (28.5)

Materials and methods

Study design and patients

SPIRIT-P1 (NCT01695239) and SPIRIT-P2 (NCT02349295) were randomised, double-blind, Phase 3 studies of ixekizumab in biologic-naive and TNFi-experienced patients with active PsA, respectively. Details regarding the 24-week double-blind treatment period have been reported previously (11, 12). Briefly, in SPIRIT-P1, patients were randomised to ixekizumab 80 mg every 4 weeks (IXEQ4W), ixekizumab 80 mg every 2 weeks (IXEQ2W), an active reference arm (adalimumab 40 mg every 2 weeks [ADAQ2W]) or placebo for 24 weeks. In SPIRIT-P2, patients were randomised to IXEQ4W, IXEQ2W or placebo for 24 weeks. Patients assigned to ixekizumab arms received 160-mg starting dose in both studies.

Common key inclusion criteria in the two studies were: patients aged ≥18 years with PsA for ≥6 months; need to meet Classification for Psoriatic Arthritis criteria (1); presence of active PsA defined as ≥3 of 68 tender joint count (TJC) and ≥3 of 66 swollen joint counts (SJC) and; presence of active psoriatic skin lesion or history of plaque psoriasis. In SPIRIT-P1, patients also had to have ≥1 joint erosion as seen on hand/foot x-rays or C-reactive protein >6mg/L. In SPIRIT-P2, treatment with ≥1 conventional disease-modifying anti-rheumatic drugs (cDMARDs) and treatment with 1-2 TNFi were other key inclusion criteria. The study protocols were approved by respective institutional review board or ethics committee at each study site. All participants provided written informed consent. Both studies were conducted in accordance with the ethical principles of the Declaration of Helsinki and in compliance with local laws and regulations (11, 12).

Assessment

In both studies, WPAI-SHP questionnaire (version 2.0) was completed by patients at baseline, and during the double-blind treatment period (Weeks 0–24) (6, 10). The questionnaire consisted of six questions that assessed the following: i) employment status (working for full pay), ii) hours missed from work due to PsA, iii) hours missed from work due to other reasons, iv) actual hours worked, v) the impact of PsA on work productivity, and vi) the impact of PsA on activities outside of work. Patients who were not currently employed could skip questions 2 to 5 and proceed to question 6. Based on the responses, percentages of absenteeism, presenteeism, work productivity loss (incorporates absenteeism and presenteeism), and activity impairment outside of work were calculated. With increases in scores, degree of impairment was greater (6, 10).

The proportions of biologic-naive and TNFi-experienced patients achieving MCID estimates at each post-baseline visit were compared across the treatment groups. MCIDs were defined as 15% improvement in work productivity loss domain and a 20% improvement in activity impairment domain scores from baseline (10).

Based on baseline Composite Psoriatic Disease Activity Index (CPDAI) scores, patients were classified as non-severe and severe (peripheral arthritis domain score ≥3 and total score ≥8) subgroups (13, 14). Proportion of patients achieving MCIDs at Week 24 in these subgroups were also assessed using integrated analysis of SPIRIT-P1 and -P2 studies to adequately power the analysis.

Statistical analysis

Patients with baseline WPAI-SHP domain scores greater than the MCID estimates were included in the analyses. Proportion of intent-to-treat patients achieving the MCIDs at Weeks 12, 16 and 24 were assessed. Treatment comparisons between active treat-
ment and placebo were done using a logistic regression model adjusting for randomisation factors. Randomisation factors included geographic region, and cDMARD experience at baseline/TNFi experience in SPIRIT-P1 and-P2 respectively. In these studies, patients who did not meet pre-specified improvement (≥20%) in TJC and SJC at Week 16 received rescue therapy and were classified as inadequate responders. Data from these patients at Week 24 were excluded. Missing values were imputed by non-responder imputation.

Two-sided $p$-values <0.05 were considered statistically significant. Treatment comparisons within CPDAI subgroups were done using Fisher’s test.

### Results

Demographics and baseline disease characteristics of patient population in SPIRIT-P1 ($n=417$) and SPIRIT-P2 ($n=363$) have been reported previously; these were balanced between treatment groups (11, 12). In SPIRIT-P1 and SPIRIT-P2, 211 (50.6%) and 162 (44.6%) patients were employed full time, and 47 (11.3%) and 37 (10.2%) patients were employed part time, respectively (Table I) (10). The baseline scores for WPAI-SHP domains for both patient populations are presented in Table I (7, 8). Proportion of patients achieving MCIDs for work productivity loss and activity impairment were higher among those with severe disease compared to non-severe disease, defined by baseline CPDAI scores (Supplementary file).

**SPIRIT-P1: Biologic-naive patients**

At Weeks 12, 16 and 24, significantly higher proportions of patients treated with IXEQ4W (Week 12: 55.1%, $p=0.021$; Week 16: 51.0%, $p=0.025$; Week 24: 57.1%, $p=0.003$) achieved the MCID for work productivity loss compared to placebo (Fig. 1A). At Weeks 16 and 24, the proportions of adalimumab-treated patients achieving MCID for work productivity loss were significantly higher (Week 16: 53.5%, $p=0.020$; Week 24: 55.8%, $p=0.008$) compared to placebo (Fig. 1A).

Proportions of patients treated with IXEQ2W who achieved MCIDs for activity impairment were significantly higher (Week 16: 46.5%, $p=0.030$; Week 24: 47.7%, $p=0.001$) compared to placebo (Fig. 2A). A similar trend was also observed with IXEQ4W at these time points. The proportions of patients treated with ADAQ2W who achieved MCIDs for activity impairment were significantly higher compared to placebo at Weeks 12 (46.5%, $p=0.030$) and 24 (47.7%, $p=0.001$) (Fig. 2A).
SPIRIT-P2: TNFi-experienced patients
At Weeks 12, 16 and 24, significantly higher proportions of patients treated with IXEQ4W (Week 12: 57.7%, p<0.001; Week 16: 50.0%, p=0.010; Week 24: 48.1%, p<0.001) achieved the MCID for work productivity loss compared to placebo (Fig. 1B). Similarly, significantly more patients achieved the MCIDs for activity impairment with IXEQ4W treatment (Week 12: 56.3%; Week 16: 54.5%; Week 24: 50.9%, p<0.001 for all) compared to placebo (Fig. 2B). A similar trend was observed in patients treated with IXEQ2W for both work productivity loss and activity impairment domains.

Discussion
Here we report that over half of biologic-naïve patients (56%) and nearly half of TNFi-experienced patients (48%) treated with ixekizumab achieved clinically meaningful improvements in work productivity loss and activity impairment domains at Week 24. Proportions of patients achieving MCID were significantly higher among those treated with IXEQ4W compared to placebo at Weeks 12, 16 and 24. These results indicate that irrespective of the type of prior drug exposure, patients with active disease would be able to attain clinically meaningful improvement in work disability. Changes in PRO measures from baseline, though statistically significant, may not be clinically meaningful. Use of responder definitions or MCIDs helps to interpret changes in PROs reported in clinical trials (15).

A major strength of this study is the use of MCIDs that were estimated using established methodologies namely, anchor-based method supplemented by the distribution-based method (10). The study assessed the MCID achievements in two different populations: biologic-naïve and TNFi-experienced patient populations. A limitation is that the analysis of MCID estimates for work productivity loss included only patients who were categorised under employment status as “work for pay” (full time/part time). In conclusion, results from Phase 3 studies suggest that treatment with ixekizumab is associated with clinically meaningful improvements in work productivity loss and activity impairment domains of WPAI-SHP among biologic-naïve and TNFi-experienced patient populations.

Acknowledgements
Writing assistance was provided by Manju Janardhanan, MD, full time employee of Eli Lilly and Company.

Data sharing statement
Lilly provides access to all individual participant data collected during the trial, after anonymisation, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has after primary publication acceptance, whichever is later. No expiration date of the MCID for work productivity loss and activity impairment domains at Week 24. Proportions of patients achieving MCID were significantly higher among those treated with IXEQ4W compared to placebo at Weeks 12, 16 and 24. These results indicate that irrespective of the type of prior drug exposure, patients with active disease would be able to attain clinically meaningful improvement in work disability. Changes in PRO measures from baseline, though statistically significant, may not be clinically meaningful. Use of responder definitions or MCIDs helps to interpret changes in PROs reported in clinical trials (15).

A major strength of this study is the use of MCIDs that were estimated using established methodologies namely, anchor-based method supplemented by the distribution-based method (10). The study assessed the MCID achievements in two different populations: biologic-naïve and TNFi-experienced patient populations. A limitation is that the analysis of MCID estimates for work productivity loss included only patients who were categorised under employment status as “work for pay” (full time/part time). In conclusion, results from Phase 3 studies suggest that treatment with ixekizumab is associated with clinically meaningful improvements in work productivity loss and activity impairment domains of WPAI-SHP among biologic-naïve and TNFi-experienced patient populations.

References